Obesity and reproductive disorders in women

Human Reproduction Update

Volumn 9, Issue 4, 2003, Pages 359-372

  Pasquali, Renato ^a   Pelusi, Carla ^a   Genghini, Silvia ^a   Cacciari, Mauro ^a   Gambineri, Alessandra ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Insulin sensitizers; Obesity; Polycystic ovary syndrome; Reproduction; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIANDROGEN; BIGUANIDE DERIVATIVE; CLOMIFENE CITRATE; CYPROTERONE ACETATE; ESTROGEN; FINASTERIDE; FLUTAMIDE; FOLLITROPIN; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN MENOPAUSAL GONADOTROPIN; INOSITOL DERIVATIVE; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR; PROGESTERONE; ROSIGLITAZONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 1; SPIRONOLACTONE; TROGLITAZONE; UNINDEXED DRUG;

ABDOMINAL DISEASE; ANOVULATION; CHILD HEALTH; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DELIVERY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GYNECOLOGIC DISEASE; HEALTH PROGRAM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INDIVIDUALIZATION; INSULIN RESISTANCE; INTRACYTOPLASMIC SPERM INJECTION; LIFESTYLE; LIVER TOXICITY; LOW CALORY DIET; MATERNAL DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PHENOTYPE; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STEROIDOGENESIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

FEMALE; HUMANS; INFERTILITY, FEMALE; OBESITY;

EID: 0041522556     PISSN: 13554786     EISSN: None     Source Type: Journal    
DOI: 10.1093/humupd/dmg024     Document Type: Review

References (193)

1. Abbott, D.H., Dumesic, D.A., Eisner, J.R., Colman, R.J. and Kemnitz, J.W. (1998) Insights into the development of PCOS from studies of prenatally androgenized female rhesus monkeys. Trends Endocrinol. Metab., 9, 62-67.
2. Abbott, D.H., Dumesic, D.A. and Franks, S. (2002) Developmental origin of polycystic ovary syndrome - a hypothesis. J. Endocrinol., 174, 1-5.
3. Acbay, O. and Gundogdu, S. (1996) Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil. Steril., 65, 946-949.
4. Agarwal, S.K., Vogel, K., Weitsman, S.R. and Magoffin, D.A. (1999) Leptin antagonizes the insulin-like growth factor-I augmentation of steroidogenesis in granulosa and theca cells of the human ovary. J. Clin. Edocrinol. Metab., 84, 1072-1076.
5. Ahima, R.S. and Flier, J.S. (2000) Leptin. Annu. Rev. Physiol., 62, 413-437.
6. Aleem, F.A. and McIntosh, T. (1984) Elevated plasma levels of β endorphins in a group of women with polycystic ovarian disease. Fertil. Steril., 42, 686-689.
7. Ariyashu, H., Takaya, K., Tagami, T. et al (2001) Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J. Clin. Endocrinol. Metab., 86, 4753-4758.
8. Armstrong, V.L., Wiggam, M.I., Ennis, C.N. et al. (2001) Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone, acetate. Q. J. Med., 94, 31-37.
9. Arvat, E., Di Vito, L., Broglio, F. et al (2000) Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J. Endocrinol. Invest., 23, 493-495.
10. Azziz R. (1989) Reproductive endocrinologic alterations in female asymptomatic obesity. Fertil. Steril., 52, 703-725.
11. Azziz, R., Ehrmann, E., Legro, R.S. et al. (2001) Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab., 86, 1626-1632.
12. Bailey, C.J. and Turner, R.C. (1996) Metformin. N. Engl. J. Med., 334, 574-579.
13. Baysal, B., Batukan, M. and Batukan, C. (2001) Biochemical and body weight changes with metformin in polycystic ovary syndrome. Clin. Exp. Obstet. Gynecol., 28, 212-214.
14. Bray, G.A. (1997) Obesity and reproduction. Hum. Reprod., 12, 26-32.
15. Bringer, J., Hedon, B., Jaffiol, C. et al. (1985) Influence of the frequency of gonadotropin-releasing hormone (GnRH) administration on ovulatory responses in women with anovulation. Fertil. Steril., 44, 42-48.
16. Bruni, V., Bucciantini, S., Caruso, S. et al. (1985) Obesity in adolescence. In: Flamigni, C., Venturoli, S. and Givens, J.R. (eds), Adolescence in Females. Year Book Medical Publisher, Chicago, pp. 309-320.
17. Brzechffa, P.R., Jakimiuk, A.J., Agarval, S.K., Weitsman, S.R., Buyalos, R.P. and Magoffin, D.A. (1996) Serum immunoreactive leptin concentrations in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 4166-4169.
18. Calandra, C., Abell, D.A. and Beischer, N.A. (1981) Maternal obesity in pregnancy. Obstet. Gynecol., 57, 8-12.
19. Campfield, L.A., Smith, F.J. and Burn, P. (1996) The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks. Horm. Metab. Res., 28, 619-632.
20. Carmina, E. (2002) Anti-androgens for the treatment of hirsutism. Expert Opin. Invest. Drugs, 11, 357-363.
21. Ciaraldi, T.P., Morales, A.J., Hickman, M.G. et al. (1997) Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J. Clin. Endocrinol. Metab., 82, 1421-1425.
22. Codsland, I.F., Walton, C., Felton, C., Proudler, A., Patel, A. and Wynn, V. (1992) Insulin resistance, secretion, and metabolism in users of oral contraceptives. J. Clin. Endocrinol. Metab., 74, 64-70.
23. Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W. and Nyce, M.R. (1996) Serum immunoreactive leptin concentrations in normal-weight and obese humans. N. Engl. J. Med., 334, 292-295.
24. Conway, G.S., Honour, J.W. and Jacobs, H.S. (1989) Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clin. Endocrinol., 30, 459-470.
25. Conway, G.S., Agrawal, R., Betteridge, D.J. et al. (1992) Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin. Endocrinol., 37, 119-125.
26. Cresswell, J.L., Barker, D.J., Osmond, C., Egger, P., Phillips, D.I. and Fraser, R.B. (1997) Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet, 350, 1131-1135.
27. Crosignani, P.G., Ragni, G., Parazzini, F. et al. (1994) Anthropometric indicators and response to gonadotropin for ovulation induction. Hum. Reprod., 9, 420-423.
28. Cummings, D.E., Purnell, J.Q., Frayo, R.S., Schmidova, K., Wisse, B.E. and Weigle, D.S. (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes, 50, 1714-1719.
29. Dahlgren, E., Landin, K., Krotkiewski, M., Holm, G. and Janson, P.O. (1998) Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod., 13, 2706-2711.
30. Dale, P.O., Tanbo, T. and Abyholm, T. (1991) In-vitro fertilization in infertile women with polycystic ovary syndrome. Hum. Reprod., 6, 238-241.
31. Dale, P.O., Tanbo, T. Haug E. and Abyholm, T. (1998) The impact of insulin resistance on the outcome of ovulation with low dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum. Reprod., 13, 567-570.
32. DeLeo, V., Lanzetta, D., Di Antona, D., La Marka, A. and Morgante, G. (1998) Hormonal effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 83, 99-102.
33. DeLeo, V., La Marca, A., Ditto, A., Morgante, G. and Cianci, A. (1999) Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil. Steril., 72, 282-285.
34. Denno, K.M. and Sadler, T.W. (1994) Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology, 49, 260-266,
35. Diamanti-Kandarakis, E., Mitrakou, A., Hennes, M.M. et al. (1995) Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism, 44, 525-531.
36. Diamanti-Kandarakis, E., Kouli, C. Tsianateli, T. and Bergiele, A. (1998a) Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. J. Endocrinol., 138, 269-274.
37. Diamanti-Kandarakis, E., Mitrakou, A., Raptis, S., Tolis, G. and Duleba, A.J. (1998b) The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 83, 2699-2705.
38. Duggal, P.S., Van Der Hoek, K.H., Milner, C.R. et al. (2000) The in-vivo and in-vitro effects of exogenous leptin on ovulation in rat. Endocrinology, 141, 1971-1976.
39. Dunaif, A. (1997) Insulin resistance and the polycystic ovary syndrome: mechanisms and implications for pathogenesis. Endocr. Rev., 18, 774-800.
40. Dunaif, A. and Finegood, D.T. (1996) β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 942-947.
41. Dunaif, A., Scott, D., Finegood, D., Quintana, B. and Whitcomb, R. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 3299-3306.
42. Ehrmann, D.A., Cavaghan, M.K., Imperial, J. et al. (1997) Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 524-530.
43. Eisner, J.R., Dumesic, D.A., Kemnitz, JW. and Abbott, D.H. (2000) Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J. Clin. Endocrinol. Metab., 85, 1206-1210.
44. El-Biely, M.M. and Habba, M. (2001) The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertil. Soc., 6, 43-49.
45. Eshel, A., Abdulwahid, N.A., Armar, N.A., Adams, J.M. and Jacobs, H.S. (1988) Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome. Fertil. Steril., 49, 956-960.
46. Evans, D.J., Hoffmann, R.G., Kalkoff, R.K. and Kissebah, A.H. (1990) Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premenopausal women. J. Clin. Endocrinol. Metab., 57, 304-310.
47. Falsetti, L., Gambera, A. and Tisi, G. (2001) Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovary syndrome. Hum. Reprod., 16, 36-42.
48. Farhi, J., Soule, S. and Jacobs, H.S. (1995) Effect of laparoscopic ovarian electrocautery on ovarian response and outcome of treatment with gonadotropins in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil. Steril., 64, 930-953.
49. Farooqi, I.S., Jebb, S.A., Langmack, G., Lawrence, E., Cheetham, C.H., Prentice, A.M., Hughes, I.A., McCamish, M.A. and O'Railly, S. (1999) Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med., 341, 879-884.
50. Fedorcsák, P., Storeng, R., Dale, P.O., Tanbo, T. and Abyholm, T. (2000a) Leptin and leptin binding activity in the preovulatory follicle of polycystic ovary syndrome patients. Scand. J. Clin. Lab. Invest., 60, 649-655.
51. Fedorcsák, P., Storeng, R., Dale, P.O. et al. (2000b) Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet. Gynecol. Scand., 79, 43-48.
52. Fedorcsák, P., Dale, P.O., Storeng, R. et al. (2001) The impact of obesity and insulin resistance on the outcome of IVF or ICSI in women with polycystic ovarian syndrome. Hum. Reprod, 16, 1086-1091.
53. Feher, T. and Bodrogi, L. (1982) A comparative study of steroid concentrations in human adipose tissue and the peripheral circulation. Clin. Chim. Acta, 126, 135-141.
54. Feldman, M., Kiser, R.S., Unger, R.H. and Li, C.H. (1983) β endorphin and the endocrine pancreas. Studies in healthy and diabetic human beings. N. Engl. J. Med., 308, 349-353.
55. Filicori, M., Flamigni, C., Meriggiola, M.C., Ferrari, P., Michelacci, L., Campaniello, E., Valdiserri, A. and Cognini, G. (1991) Endocrine response to determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders. J. Clin. Endocrinol. Metab., 72, 965-972.
56. Filicori, M., Flamigni, C., Dellai, P., Cognini, G., Michelacci, L., Amone, R., Sambataro, M. and Falbo, A. (1994) Treatment of anovulation with pulsative gonadotropin-releasing hormone prognostic factors and clinical results in 600 cycles. J. Clin. Endocrinol. Metab., 79, 1215-1220.
57. Fishman, J. (1985) Alteration in estrogen metabolism induced by body weight changes: implication in puberty. In: Flamigni, C., Venturoli, S. and Given, J.R. (eds), Adolescence in Females. Year Book Medical Publisher, Chicago, pp. 117-130.
58. Fleming, R., Hopkinson, Z.E., Wallace, R.E. et al. (2002) Ovarian function and metabolic factors in women with oligoamenorrhea treated with metformin in a randomized double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab., 87, 569-574.
59. Franks, S. (1989) Polycystic ovary syndrome: a changing perspective. Clin. Endocrinol., 31, 87-120.
60. Friedman, J.M. and Halaas, J.L. (1998) Leptin and the regulation of body weight in mammals. Nature, 395, 763-770.
61. Fridstom, M., Sjoblom, P., Pousette, A. and Hillensjo, T. (1997) Serum FSH levels in women with polycystic ovary syndrome during ovulation induction using down-regulation and urofollitropin. Eur. J. Endocrinol., 136, 488-492.
62. Frisch, R.E. (1980) Pubertal adipose tissue: is it necessary for normal sexual maturation? Evidence from the rat and human female. Fed. Proc., 39, 2395-2400.
63. Frisch, R.E. and McArthur, J.W. (1974) Menstrual cycle: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science, 185, 949-951.
64. Galtier-Dereure, F., Mantpeyroux, F., Boulat, P., Bringer, J. and Jaffol, C. (1995) Weight excess before pregnancy: complications and cost. Int. J. Obesity, 19, 443-448.
65. Galtier-Dereure, F., Pujol, P., Dewailly, D. et al. (1997) Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum. Reprod., 12, 88-96.
66. Gambineri, A., Pelusi, C., Vicennati, V., Pagotto, U. and Pasquali, R. (2002a) Obesity and the polycystic ovary syndrome. Int. J Obesity, 26, 883-896.
67. Gambineri, A., Pelusi, C., Vicennati, V., Pagotto U. and Pasquali, R. (2002b) Flutamide and Metformin added to low-calorie diet in the treatment of obese women with PCOS. 9th International Congress of Obesity, San Paulo, Brasil. Int. J. Obesity, 26, S81.
68. Genazzani, A.R., Facchinetti, F., Petraglia, F., Pintor, C. and Corda, R. (1986) Hyperendorphinemia in obese children and adolescents. J. Clin. Endocrinol. Metab., 62, 36-40.
69. Giuliano, D. (1984) Morphine, opioid peptides and pancreatic islet function. Diabetes Care, 7, 92-98.
70. Giuliano D., Salvatore, T., Cozzolino, D., Ceriello, A., Torella R. and D'Onofrio, F. (1987) Sensitivity to β-endorphins as a cause of human obesity. Metabolism, 36, 974-978.
71. Giuliano, D., Cozzolino, D. and Torella, R. (1989) Arguments for a role of opioid peptides in some pathogenetic events of obesity. In: Lardy, H. and Stratmen, F. (eds), Hormones, Thermogenesis, and Obesity. Elsevier Science, New York, pp. 209-218.
72. Glüeck, C.J., Wang, P., Fontaine, R., Tracy, T. and Sieve-Smith, L. (1999a) Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism, 48, 511-519.
73. Glüeck, C.J., Wang, P., Fontaine, R.N., Sieve-Smith, L., Tracy, T. and Moore, S.K. (1999b) Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism, 48, 1589-1595.
74. Glüeck, C.J., Phillips, H., Cameron, D., Sieve-Smith, L. and Wang, P. (2001a) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil. Steril., 75, 46-52.
75. Glüeck, C.J., Wang, P., Fontaine, R., Tracy, T. and Sieve-Smith, L. (2001b) Metformin to restore normal menses in oligomenorrheic teenage girls with polycystic ovary syndrome (PCOS). J. Adolesc. Health, 29, 160-169.
76. Glüeck, C.J., Streicher, P. and Wang, P. (2002a) Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin. Pharmacother., 3, 1177-1189.
77. Ghüeck, C.J., Wang, P., Goldenberg, N. and Sieve-Smith, L. (2002b) Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum. Reprod., 17, 2858-2864.
78. Grulet, H., Heeart, A.C., Delemer, B. et al. (1993) Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin. Endocrinol., 38, 621-626.
79. Hamilton-Fairley, D. and Franks, S. (1994) The role of body weight and metabolic anomalies in ovulation induction. Contracept. Fertil. Sex., 22, 178-179.
80. Hammond, M.G., Halme, J.K. and Talbert, L.M. (1983) Factors affecting the pregnancy rate in clomiphene citrate induction ovulation. Obstet. Gynecol., 62, 196-202.
81. Hartz, A.J., Barboriak, P.N., Wong, A., Katayama, K.P. and Rimm, A.A. (1979) The association of obesity with infertility and related menstrual abnormalities in women. Int. J. Obesity, 3, 57-77.
82. Harris, R.B.S. (2000) Leptin-much more than a satiety signal. Annu. Rev. Nutr., 20, 45-75.
83. Heard, M.J., Pierce, A., Carson, S.A. and Buster, J.E. (2002) Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil. Steril., 77, 669-673.
84. Holte, J., Bergh, T., Gennarelli, G. et al. (1994) The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin. Endocrinol., 41, 473-481.
85. Holte, J., Bergh, T., Berne, C. et al. (1995) Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 80, 2586-2593.
86. Homburg, R., Orvieto, R., Bar-Hava, I. and Ben-Rafael, Z. (1996) Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophin in women with polycystic ovary syndrome. Hum. Reprod., 11, 716-719.
87. Howard, A.D., Feighner, S.D., Cully, D.F. et al. (1996) A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 273, 974-977.
88. Huber-Buchholz, M.M., Carey, D.G.P. and Norman, R.J. (1999) Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab., 84, 1470-1474.
89. Ibánez, I., Potau, N., Marcos, M.V. and De Zegher, F. (2000a) Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in non-obese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab., 85, 3251-3255.
90. Ibánez, L., Valls, C., Potau, N., Marcos, M.V. and De Zegher, F. (2000b) Sensitization to insulin in adolescent girls to normalize hirsutism, oligoamenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J. Clin. Endocrinol. Metab., 85, 3526-3530.
91. Ibánez, L., Valls, C., Ferrer, A., Marcos, M.V., Rodriguez-Hierro, F. and De Zegher, F. (2001) Sensitization to insulin induces ovulation in non obese adolescents with anovulatory hyperandrogenism. J. Clin. Endocrinol. Metab., 86, 3595-3598.
92. Ibánez, L., Valls, C., Ferrer, A., Ong, K., Dunger, D.B. and De Zegher, F. (2002) Additive effects of insulin-sensitizing and anti-androgen treatment in young, non obese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J. Clin. Endocrinol. Metab., 87, 2870-2874.
93. Imani, B., Eijkemans, M.J., Te Velde, E.R., Habbema, J.D. and Fauser, B.C. (1998) Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. J. Clin. Endocrinol. Metab., 83, 2361-2365.
94. Imani, B., Eijkemans, M.J.C., Jong, F.H., Payne, N.N., Bouchard, P., Giudice, L.C. and Fauser, B.C.J.M. (2000) Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction ovulation in normogonadotropic oligoamenorrheic infertility. J. Clin. Endocrinol. Metab., 85, 676-682.
95. Imperato-McGinley, J., Sanchez, R.S., Spencer, J.R. et al. (1992) Comparison of the effects of the 5α-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and fetal differentiation: dose-response studies. Endocrinology, 131, 1149.
96. Iuorno, M.J. and Nestler, J.E. (2001) Insulin lowering drugs in polycystic ovary syndrome. Obstet. Gynecol. Clin. North Am., 28, 153-164.
97. Jakubowicz, D.J., Seppala, M., Jakubowicz, S. et al. (2001) Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 86, 1126-1133.
98. Jakubowicz, D.J., Iuorno, M.J., Jakubowicz, S., Roberts, K.A. and Nestler, J.E. (2002) Effects of metformin on early pregnancy loss in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 87, 524-529.
99. Jewelowicz, R. (1984) The role of endogenous opioid peptides in control of the menstrual cycle. Fertil. Steril., 42, 683-685.
100. Kallen, K. (1998) Maternal smoking, body mass index, and neural tube defects. Am. J. Epidemiol., 147, 1103-1111.
101. Kalkhoff, R.K. (1991) Impact of maternal fuels and nutritional state on fetal growth. Diabetes, 40, 61-65.
102. Karlsson, C., Lindell, K., Svensson, E. et al. (1997) Expression of functional leptin receptors in the human ovary. J. Clin. Endocrinol. Metab., 82, 4144-4148.
103. Kirschner, M.A. (1982) Obesity, androgens, oestrogens, and cancer risk. Cancer Res., 42, 3281-3285.
104. Kirschner, M.A., Samojlik, E., Drejka, M., Szmal, E., Schneider, G. and Ertel, N. (1990) Androgen-estrogen metabolism in women with upper body versus lower body obesity. J. Clin. Endocrinol. Metab., 70, 473-479.
105. Kocak, M., Caliskan, E., Simsir, C. and Haberal, A. (2002) Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil. Steril., 77, 101-106.
106. Kojima, M., Hosoda, H., Date, Y., Najazato, M., Matsuo, H. and Kangawa, K. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature, 402, 656-660.
107. Kolodziejczyk, B., Duleba, A.J., Speczynski, R.Z. and Pawelczyk, L. (2000) Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril., 73, 1149-1154.
108. Kousta, E., White, D.M. and Franks, S. (1997) Modern use of clomiphene citrate in induction of ovulation. Hum. Reprod. Update, 3, 359-365.
109. LaMarca, A., Morgante, G., Paglia, T., Ciatta, L., Cianci, A. and De Leo, V. (1999) Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fertil. Steril., 72, 985-989.
110. Lake, J.K., Power, C. and Cole, T.J. (1997) Women's reproductive health-the role of body mass index in early and adult life. Int. J. Obesity, 21, 432-438.
111. Larner, J. (1994) Multiple pathways in insulin signalling-fitting the covalent and allosteric puzzle pieces together. Endocr. J., 2, 167-171.
112. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Wilson, T.M. and Kliewer, S.A. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferation-activated receptor γ (PPARγ). J. Biol. Chem., 270, 12953-12956.
113. Lobo, R.A., Gysler, M., March, C.M., Goebelsmann, U. and Mishell, D.R. (1982) Clinical and laboratory predictors of clomiphene response. Fertil. Steril., 37, 168-174.
114. Lucas, A., Morley, R., Cal, T.J., Bamford, M.F., Boon, A., Crowle, P., Dossetor, J.F. and Pearse, R. (1988) Maternal fatness and nativity of preterm infants. Br. Med. J. (Clin. Res. Ed.), 296, 1495-1497.
115. Mahabeer, S., Naidoo, C., Norman, R.J. et al. (1990) Metabolic profiles and lipoprotein lipid concentrations in nonobese and obese patients with polycystic ovary syndrome. Horm. Metab. Res., 22, 537-540.
116. Mastorakos, G., Koliopoulos, C. and Creatsas, G. (2002) Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined contraceptives. Fertil. Steril., 77, 919-927.
117. McClure, N., McQuin, B., McDonald, J., Kovas, G.T., Healy, D.L. and Burger, H.G. (1992) Body weight, body mass index, and age: predictors of menotropin dose and cycle outcome in polycystic ovarian syndrome? Fertil. Steril., 58, 622-624.
118. Millis C.L. (1992) Factors affecting embryological parameters and embryo selection for IVF-ET. In: Brindes, P.R. and Rainsbury, P.A. (eds), A Textbook of In Vitro Fertilization and Assisted Reproduction. Partheon, Carnforth, pp. 187-204.
119. Mitwally, M.F., Kuseu, N.K. and Yaleinkaya, T.M. (1999) High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum. Reprod., 14, 2700-2703.
120. Miyata, K., Yabushita, S., Sukata, T., Sauo, M., Yoshino, H., Nakauishi, T., Okuno, Y. and Matsuo, M. (2002) Effects of perinatal exposure to flutamide on sex hormones and androgen-dependent organs in F1 male rats. J. Toxicol. Sci., 27, 19-33.
121. Moghetti, P., Tosi, F., Castello, R. et al. (1996) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J. Clin. Endocrinol. Metab., 81, 952-960.
122. Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E. and Muggeo, M. (2000) Metformin effects on clinical, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab., 85, 139-146.
123. Montemagno, U., Contaldo, F., Martinelli, P. and Votino, F. (1979) Gynecological complications of obesity. In: Mancini, M., Lewis, B. and Contaldo, F. (eds), Medical Complications of Obesity. Academic Press, London, pp. 227-283.
124. Morales, A.J., Laughlin, G.A., Båtzow, T. et al. (1996) Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J. Clin. Endocrinol. Metab., 81, 2854-2864.
125. Moran, L.J., Noakes, M., Clifton, P.M., Tomlinson, L. and Norman, R.J. (2003) Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 88, 812-819.
126. Morin-Papunen, L.C., Koivunen, R.M., Ruokonen, A. and Martikainen, H.K. (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil. Steril., 69, 691-696.
127. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M. et al. (2000a) Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Hum. Reprod., 15, 1266-1274.
128. Morin-Papunen, L.C., Vauhkonen, I., Koivunen, R.M., Ruokonen, A., Martikainen, H.K. and Tapanainen, J.S. (2000b) Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab., 85, 3161-3165.
129. Nestler, J.E. and Jakubowicz, D.J. (1996) Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N. Engl. J. Med., 335, 617-623.
130. Nestler, J.E. and Jakubowicz, D.J. (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450cl7α activity and serum androgens. J. Clin. Endocrinol. Metab., 82, 4075-4079.
131. Nestler, J.E., Jakubowicz, D.J., De Vergas, A.F., Brik, C., Quintiero, N. and Medina, F. (1998a) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J. Clin. Endocrinol. Metab., 83, 2001-2005.
132. Nestler, J.E., Jakubowicz, D.J., Evans, W.S. and Pasquali, R. (1998b) Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N. Engl. J. Med, 338, 1876-1880.
133. Nestler, J.E., Jakubowicz, D.J., Reamer, P., Gunn, R.D. and Allan, G. (1999) Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N. Engl. J. Med., 340, 1314-1320.
134. Ng, E.H., Wat, N.M. and Ho, P.C. (2001) Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum. Reprod, 16, 1625-1631.
135. Norman, R.J. and Clark, A.M. (1998) Obesity and reproductive disorders: a review. Reprod. Fertil. Dev., 10, 55-63.
136. Opsahl, M.S., Robins, E.D., O'Connor, D.M., Scott, R.T. and Fritz, M.A. (1996) Characteristics of gonadotropin response, follicular development, and endometrial growh and maturation across consecutive cycles of clomiphene citrate treatment. Fertil. Steril., 66, 533-539.
137. O'Railly, S. (1998) Life without leptin. Nature, 392, 330-331.
138. Odling, V., Milsom, I., Persson, I. and Victor, A. (2002) Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Gynecol. Scand., 81, 482-490.
139. Padmanabhan, V., Evans, N., Taylor, J.A. and Robinson, J.E. (1998) Prenatal exposure to androgens leads to the development of cystic ovaries in the sheep. Biol. Reprod., 56, 194.
140. Pagotto, U., Gambineri, A., Vicennati, V., Heiman, M.L., Tschoep, M. and Pasquali, R. (2002) Ghrelin, obesity and the polycystic ovary syndrome: correlations with insulin resistance and androgen levels. J. Clin. Endocrinol. Metab., 87, 5625-5629.
141. Paoletti, A.M., Cagnacci, A., Orru, M., Ajossa, S., Guerriero, S. and Melis, G.B. (1999) Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil. Steril., 72, 448-453.
142. Papotti, M., Ghe, C., Cassoni, P., Catapano, F., Deghenghi, R., Ghigo, E. and Muccioli, G. (2000) Growth hormone secretagogue binding sites in peripheral human tissues. J. Clin. Endocrinol. Metab., 85, 3803-3807.
143. Parsanezhad, M.E., Alborzi, S., Zarei, A., Dehabashi, S. and Omrani, G. (2001) Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int. J. Gynecol. Obstet., 75, 43-50.
144. Pasquali, R. and Casimirri, F. (1993) The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin. Endocrinol. (Oxf.), 39, 1-16.
145. Pasquali, R. and Gambineri, A. (2002) Treatment of the polycystic ovary syndrome with lifestyle intervention. Curr. Opin. Endocrinol. Diabetes, 9, 459-468.
146. Pasquali, R., Casimirri, F., Antenucci, D., Melchionda, N., Colombi, C. and Gaddi, D. (1985) Relationship between onset of obesity and onset of oligomenorrhea in females with obesity and polycystic ovaries. In: Flamigni, C., Venturoli, S. and Givens, Givens (eds), Adolescence in Females. Year Book Medical Publisher, Chicago, pp. 363-365.
147. Pasquali, R., Antenucci, D., Casimirri, F. et al. (1989) Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J. Clin. Endocrinol. Metab., 68, 173-179.
148. Pasquali, R,. Casimirri, F., Platè, L. and Capelli, M. (1990) Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm. Metab. Res., 22, 303-306.
149. Pasquali, R., Cantobelli, S., Casimirri, F., Bortoluzzi, L., Boschi, S., Capelli, M., Melchionda, K. and Barbara, L. (1992) The role of the opioid peptides in the development of hyperinsulinemia in obese women with abdominal body fat distribution. Metabolism, 41, 763-767.
150. Pasquali, R., Casimirri, F., Cantobelli, S. et al. (1993) Insulin and androgen relationships with abdominal body fat distribution in women with and without hyperandrogenism. Horm. Res., 39, 179-187.
151. Pasquali, R., Gambineri, A., Biscotti, D. et al. (2000) Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 85, 2767-2774.
152. Pasquali, R., Vicennati, V. and Pagotto, U. (2003) Endocrine determinants of fat distribution. In: Bary, G.A. (ed.), Handbook of Obesity, 2nd edition. Marcel Dekker, New York (in press).
153. Pirwany, I.R., Yates, R.W.S., Cameron, I.T. and Fleming, R. (1999) Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea. Hum. Reprod., 14, 2963-2968.
154. Polson, D.W., Kiddy, D.S., Mason, H.D. and Franks, S. (1989) Induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome: the difference between responders and non responders. Fertil. Steril., 51, 30-34.
155. Porestky, L. and Piper, B. (1994) Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet. Gynecol., 84, 613-621.
156. Poretsky, L., Cataldo, N.A., Rosenwaks, Z. and Giudice, L.C. (1999) The insulin-related ovarian regulatory system in health and disease. Endocr. Rev., 20, 535-582.
157. Prentice, A. and Goldberg, G. (1996) Maternal obesity increases congenital malformations. Nutr. Rev., 54, 146-152.
158. Rich-Edwards, J.A., Goldman, M.B., Willet, W.C., Huntere, D.J., Stampfer, M.J., Colditz, G.A. and Manson, J.E. (1994) Adolescent body mass index and infertility caused by ovulatory dysfunction. Am. J. Obstet. Gynecol., 71, 171-177.
159. Robinson, J.E., Forsdike, R.A. and Taylor, J.A. (1999) In-utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology, 140, 5797-5805.
160. Rogers, J. and Mitchell, G.W. (1952) The relation of obesity to menstrual disturbances. N. Engl. J. Med., 247, 53-56.
161. Samojlik, E., Kirschner, M.A., Silber, D., Scneider, G. and Ertel, N.H. (1984) Elevated production and metabolic clearance rates of androgens in morbidly obese women. J. Clin. Endocrinol. Metab., 59, 949-954.
162. Shaw, G.M., Velie, E.M. and Schaffer, D. (1996) Risk of neural tube defect-affected pregnancies among obese women. JAMA, 275, 1093-1096.
163. Shiiya, T., Nakazato, M., Minuza, M. et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab., 87, 240-244.
164. Smith, S.R. (1996) The endocrinology of obesity. Endocrinol. Metab. Clin. North Am., 25, 921-942.
165. Spicer, L.J. and Francisco, C.C. (1997) The adipose obese gene product, leptin: evidence of a direct inhibitory role in ovarian function. Endocrinology, 138, 3374-3379.
166. Spicer, L.J. and Francisco, C.C. (1998) Adipose tissue product, leptin, inhibits bovine ovarian thecal cell steroidogenesis. Biol. Reprod., 58, 207-212.
167. Stadtmauer, L.A., Toma, S.K., Riehl, R.M. and Talbert, L.M. (2001) Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil. Steril., 75, 505-509.
168. Stein, I.F. and Leventhal, M.L. (1934) Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol., 29, 181-191.
169. Tena-Sempere, M., Barreio, M.L., Gonzalez, L.C. et al. (2002) Novel expression and functional role of ghrelin in rat testis. Endocrinology, 143, 717-725.
170. Tschop, M., Smiley, D.L. and Heiman, M.L. (2000) Ghrelin induces adiposity in rodents. Nature, 407, 908-913.
171. Tschop, M., Weyer, C., Tataranni, A.P., Devanarayan, V., Ravussin, E. and Heiman, M.L. (2002) Circulating ghrelin levels are decreased in human obesity. Diabetes, 50, 707-709.
172. Unluhizuci, K., Klestimur, F., Bayram, F., Sahin, Y. and Futus, A. (1999) The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. Clin. Endocrinol., 51, 231-236.
173. Vandermolen, D.T., Ratts, V.S., Evans, W.S., Stvall, D.W., Kauma, S.W. and Nestler, J.E. (2001) Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil. Steril., 75, 310-315.
174. Velazquez, E.M., Mendoza, S., Hamer, T., Sosa, F. and Glüeck, C.J. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654.
175. Velazquez, E.M., Mendoza, S.G., Wang, P. and Glüeck, C.J. (1997a) Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism, 46, 454-457.
176. Velazquez, E.M., Acosta, A. and Mendoza, S.G. (1997b) Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol., 90, 392-395.
177. Vicennati, V., Gambineri, A., Calzoni, F., Casimirri, F., Macor C., Vettor, R. and Pasquali R. (1998) Serum leptin in obese women with polycystic ovary syndrome is correlated with body weight and fat distribution but not with androgen and insulin levels. Metabolism, 47, 988-992.
178. VonShoultz, B. and Calstrom, K. (1989) On the regulation of sex-hormone-binding globulin. A challenge of old dogma and outlines of an alternative mechanism. J. Steroid Biochem., 32, 327-334.
179. Vrbikova, J., Hill, M., Starka, L., Cibula, D., Bendlova, B., Vondra, K., Sulcova, J. and Snajderova, M. (2001) The effects of long-term metformin treatment and adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur. J. Endocrinol., 144, 619-628.
180. Vrbikova, J., Hill, M., Stuka, L. and Vandra, K. (2002) Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. Gynecol. Obstet. Invest., 53, 100-104.
181. Wajchenberg, B.L. (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev., 21, 697-738.
182. Waller, D.K., Mills, U., Simpson, J.L. et al. (1994) Are obese women at higher risk for producing malformed offspring? Am. J. Obstet. Gynecol., 170, 541-548.
183. Wang, JX, Davies, M.J. and Norman, R.J. (2001) Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum. Reprod., 16, 2606-2609.
184. Wass, P., Waldenstrom, U., Rossner, S. and Hellberg, D. (1997) An android body fat distribution in females impairs the pregnancy rate in-vitro fertilization-embryo transfer. Hum. Reprod., 12, 2057-2060.
185. Watkins M.L., Scanlon, K.S., Mulinare, J. and Khroury, M.J. (1996) Is maternal obesity a risk factor for anencephaly and spina bifida? Epidemiology, 7, 507-512.
186. Werler, M.M., Louik, C., Shapiro, S. and Mitchell, A.A. (1996) Prepregnant weight in relation to risk of neural tube defects. JAMA, 275, 1089-1092.
187. White, D.M., Polson, D.W., Kiddy, D., Sagle, P., Watson, H., Gilling-Smith, C., Hamilton-Fairley, D. and Franks, S. (1996) Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J. Clin. Endocrinol. Metab., 81, 3821-3824.
188. Wiesner, G., Vaz, M., Collier, G. et al. (1999) Leptin is released from the human brain: influence of adiposity and gender. J. Clin. Endocrinol. Metab., 84, 2270-2274.
189. World Health Organization (1997) Preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva, WHO/NUT/NCD/98.1.
190. Wren, A.M., Seal, L.J., Cohen, M.A. et al. (2001) Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab., 86, 5992-5995.
191. Yarali, H., Yildiz, B.O., Demirol, A., Zeyneloglu, H.B,, Yigit, N., Bukulmez, O. and Koray, Z. (2002) Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Hum. Reprod., 17, 289-294.
192. Yen, S.S.C. (1980) The polycystic ovary syndrome. Clin. Endocrinol. (Oxf.), 12, 177-208.
193. Zaadstra, B.M., Seidell, J.C., Van Noord, P.A., Te Velde, E.R., Habbema, J.D., Vrieswijk, B. and Karbaat, J. (1993) Fat and female fecundity: prospective study of effect of body fat distribution on conception rates. Br. Med. J., 306, 484-487.